Vivet Therapeutics

Gene therapy
#Award #Career #Gene therapy #Genetics / genomics #Vivet Therapeutics

Dr Gonzalez-Aseguinolaza recognised for gene therapy research

Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer of Vivet Therapeutics, has been awarded the Rosalind Franklin Society (RFS) Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society. The award recognises Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific… Read More

#News

Neuroscience
#Cerebrotendinous xanthomatosis #Funding #Gene therapy #Neurodegenerative disorders #Neuroscience #Vivet Therapeutics

Funds advance gene therapy for cerebrotendinous xanthomatosis 

Vivet Therapeutics has received €4.9 million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.   This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy… Read More

#Business & Investment #News